$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

$enta Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000095017024131260 Filed on November 27, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024
Revenue		$14.61M	$67.64M
YoY Change		-22.84%	-14.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$13.68M	$57.85M
YoY Change		-0.85%	9.36%
% of Gross Profit
Research & Development		$30.78M	$131.5M
YoY Change		-14.91%	-19.6%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$44.46M	$131.5M
YoY Change		-11.01%	-19.6%
Operating Profit			-$121.7M
YoY Change			-11.31%
Interest Expense		$668.0K	$3.903M
YoY Change		-55.76%	-24.18%
% of Operating Profit
Other Income/Expense, Net			$3.903M
YoY Change			-37.17%
Pretax Income		-$29.19M	-$117.8M
YoY Change		-1.13%	-10.08%
Income Tax		-$363.0K	-$1.743M
% Of Pretax Income
Net Earnings		-$28.82M	-$116.0M
YoY Change		2.54%	-13.28%
Net Earnings / Revenue		-197.32%	-171.58%
Basic Earnings Per Share			-$5.48
Diluted Earnings Per Share		-$1.36	-$5.48
COMMON SHARES
Basic Shares Outstanding	21.19M	21.19M	21.16K
Diluted Shares Outstanding			21.16K

Balance Sheet

Concept	2024 Q3	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$248.2M	$248.2M
YoY Change	-32.91%	-32.9%
Cash & Equivalents	$37.23M	$37.23M
Short-Term Investments	$211.0M	$211.0M
Other Short-Term Assets	$13.02M	$13.02M
YoY Change	-2.1%	-2.1%
Inventory
Prepaid Expenses
Receivables	$6.646M	$6.646M
Other Receivables	$32.00M	$32.00M
Total Short-Term Assets	$299.9M	$299.9M
YoY Change	-29.08%	-29.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$32.69M	$73.35M
YoY Change	174.25%	111.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$94.00K	$3.454M
YoY Change	-88.29%	-28.04%
Total Long-Term Assets	$76.80M	$76.80M
YoY Change	94.51%	94.43%
TOTAL ASSETS
Total Short-Term Assets	$299.9M	$299.9M
Total Long-Term Assets	$76.80M	$76.80M
Total Assets	$376.7M	$376.7M
YoY Change	-18.52%	-18.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.002M	$8.002M
YoY Change	95.31%	95.17%
Accrued Expenses	$13.55M	$15.07M
YoY Change	-26.13%	-36.14%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$57.54M	$57.54M
YoY Change	-8.36%	-8.38%
LONG-TERM LIABILITIES
Long-Term Debt	$1.350M	$1.350M
YoY Change	-3.57%	-3.57%
Other Long-Term Liabilities	$231.0K	$189.0M
YoY Change	-65.16%	4.22%
Total Long-Term Liabilities	$231.0K	$190.3M
YoY Change	-65.16%	4.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.54M	$57.54M
Total Long-Term Liabilities	$231.0K	$190.3M
Total Liabilities	$247.8M	$247.8M
YoY Change	0.94%	0.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$323.0M
YoY Change	56.06%
Common Stock	$451.6M
YoY Change	6.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$128.8M	$128.8M
YoY Change
Total Liabilities & Shareholders Equity	$376.7M	$376.7M
YoY Change	-18.52%	-18.53%

Cashflow Statement

Concept	2024 Q3	2024
OPERATING ACTIVITIES
Net Income	-$28.82M	-$116.0M
YoY Change	2.54%	-13.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$78.76M
YoY Change		-23.64%
INVESTING ACTIVITIES
Capital Expenditures		$17.95M
YoY Change		98.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$58.24M
YoY Change		-208.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-27.63M
YoY Change		-113.94%
NET CHANGE
Cash From Operating Activities		-78.76M
Cash From Investing Activities		58.24M
Cash From Financing Activities		-27.63M
Net Change In Cash		-48.16M
YoY Change		-216.33%
FREE CASH FLOW
Cash From Operating Activities		-$78.76M
Capital Expenditures		$17.95M
Free Cash Flow		-$96.71M
YoY Change		-13.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001177648
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-35839
CY2024	dei	Entity Registrant Name EntityRegistrantName	ENANTA PHARMACEUTICALS, INC
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3205099
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Kingsbury Avenue
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2024	dei	City Area Code CityAreaCode	617
CY2024	dei	Local Phone Number LocalPhoneNumber	607-0800
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2024	dei	Trading Symbol TradingSymbol	ENTA
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	347379533
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21194326
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	dei	Auditor Firm AuditorFirmId	238
CY2024	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2024	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37233000
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85388000
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	210953000
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	284522000
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6646000
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8614000
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12413000
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13263000
CY2024Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	31999000
CY2023Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	31004000
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	608000
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0
CY2024Q3	us-gaap	Assets Current AssetsCurrent	299852000
CY2023Q3	us-gaap	Assets Current AssetsCurrent	422791000
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32688000
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11919000
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40658000
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22794000
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3360000
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3968000
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	94000
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	803000
CY2024Q3	us-gaap	Assets Assets	376652000
CY2023Q3	us-gaap	Assets Assets	462275000
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8002000
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4097000
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13547000
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18339000
CY2024Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	34462000
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	35076000
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1524000
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5275000
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	57535000
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	62787000
CY2024Q3	enta	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	134779000
CY2023Q3	enta	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	159429000
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53943000
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21238000
CY2024Q3	enta	Non Convertible Preferred Stock Liabilities NonConvertiblePreferredStockLiabilities	1350000
CY2023Q3	enta	Non Convertible Preferred Stock Liabilities NonConvertiblePreferredStockLiabilities	1423000
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	231000
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	663000
CY2024Q3	us-gaap	Liabilities Liabilities	247838000
CY2023Q3	us-gaap	Liabilities Liabilities	245540000
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21194000
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21194000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21059000
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21059000
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	212000
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	211000
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	451340000
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	424693000
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	302000
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1174000
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-323040000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-206995000
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	128814000
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	216735000
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	376652000
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	462275000
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	67635000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79204000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86160000
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	131476000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	163524000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	164522000
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57850000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	52887000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45482000
CY2024	us-gaap	Costs And Expenses CostsAndExpenses	189326000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	216411000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	210004000
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-121691000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-137207000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-123844000
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10940000
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	5148000
CY2022	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0
CY2024	us-gaap	Investment Income Net InvestmentIncomeNet	14770000
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	11360000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	1573000
CY2024	enta	Fair Value Adjustment Nonconvertible Preferred Stock FairValueAdjustmentNonconvertiblePreferredStock	73000
CY2023	enta	Fair Value Adjustment Nonconvertible Preferred Stock FairValueAdjustmentNonconvertiblePreferredStock	0
CY2022	enta	Fair Value Adjustment Nonconvertible Preferred Stock FairValueAdjustmentNonconvertiblePreferredStock	83000
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3903000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6212000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1656000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-117788000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-130995000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-122188000
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1743000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2821000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-433000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-116045000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-133816000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121755000
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.48
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.48
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.38
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.38
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.91
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.91
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21157
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21157
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20969
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20969
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20603
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20603
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-116045000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-133816000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121755000
CY2024	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1476000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2550000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3342000
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1476000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2550000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3342000
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114569000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-131266000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125097000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	399429000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21262000
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1229000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26969000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3342000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-121755000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	321334000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2208000
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-3757000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28216000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2550000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-133816000
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	216735000
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	147000
CY2024	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-294000
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26795000
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1476000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-116045000
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	128814000
CY2024	us-gaap	Profit Loss ProfitLoss	-116045000
CY2023	us-gaap	Profit Loss ProfitLoss	-133816000
CY2022	us-gaap	Profit Loss ProfitLoss	-121755000
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	26795000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	28216000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	26969000
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2336000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2371000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2973000
CY2024	enta	Non Cash Interest Expense Associated With The Sale Of Future Royalties NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties	-135000
CY2023	enta	Non Cash Interest Expense Associated With The Sale Of Future Royalties NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties	5148000
CY2022	enta	Non Cash Interest Expense Associated With The Sale Of Future Royalties NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties	0
CY2024	enta	Payments For Royalty Liabilities PaymentsForRoyaltyLiabilities	-2350000
CY2023	enta	Payments For Royalty Liabilities PaymentsForRoyaltyLiabilities	10318000
CY2022	enta	Payments For Royalty Liabilities PaymentsForRoyaltyLiabilities	0
CY2024	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	0
CY2023	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	73000
CY2022	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	846000
CY2024	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1138000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2856000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1171000
CY2024	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-16000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-150000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2024	enta	Fair Value Adjustment Nonconvertible Preferred Stock FairValueAdjustmentNonconvertiblePreferredStock	73000
CY2023	enta	Fair Value Adjustment Nonconvertible Preferred Stock FairValueAdjustmentNonconvertiblePreferredStock	-0
CY2022	enta	Fair Value Adjustment Nonconvertible Preferred Stock FairValueAdjustmentNonconvertiblePreferredStock	83000
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1968000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11704000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3258000
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-850000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-182000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-743000
CY2024	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	995000
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2286000
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-8537000
CY2024	enta	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-6096000
CY2023	enta	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-4598000
CY2022	enta	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-4776000
CY2024	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-709000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	107000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	604000
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-414000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1151000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4634000
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5646000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2558000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1477000
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4994000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2567000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3706000
CY2024	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-432000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	209000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-104000
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78764000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103154000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84782000
CY2024	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	307282000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	373391000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	171446000
CY2024	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	383465000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	328871000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	228468000
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17948000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9058000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2125000
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58235000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53578000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54897000
CY2024	enta	Payments On Royalty Sale Liability Net Of Imputed Interest PaymentsOnRoyaltySaleLiabilityNetOfImputedInterest	27479000
CY2023	enta	Payments On Royalty Sale Liability Net Of Imputed Interest PaymentsOnRoyaltySaleLiabilityNetOfImputedInterest	0
CY2022	enta	Payments On Royalty Sale Liability Net Of Imputed Interest PaymentsOnRoyaltySaleLiabilityNetOfImputedInterest	0
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	147000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2208000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21262000
CY2024	enta	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	0
CY2023	enta	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	200000000
CY2022	enta	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	0
CY2024	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	325000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2024	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	294000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3757000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1229000
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27626000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	198126000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20033000
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48155000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41394000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9852000
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	89356000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47962000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	57814000
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41201000
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	89356000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47962000
CY2024	us-gaap	Income Taxes Paid IncomeTaxesPaid	241000
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	4899000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2024	us-gaap	Interest Paid Net InterestPaidNet	11710000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1987000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0
CY2024	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-9358000
CY2023	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-1994000
CY2022	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0
CY2024	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5597000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	424000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1215000
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23960000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3817000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23910000
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enanta Pharmaceuticals, Inc. (collectively with its subsidiary, the “Company”</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), incorporated in Delaware in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1995</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, is a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs with an emphasis on virology and immunology. The Company discovered glecaprevir, the second of two antiviral protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie’s leading brand of direct-acting antiviral, or DAA, combination treatment for HCV, which has been marketed under the tradenames MAVYRET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (U.S.) and MAVIRET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ex-U.S.) (glecaprevir/pibrentasvir) since 2017.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to many of the risks common to companies in the biotechnology industry, including but not limited to, the uncertainties of research and development, competition from technological innovations of others, dependence on collaborative arrangements, protection of proprietary technology, dependence on key personnel and compliance with government regulation. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approvals, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance reporting capabilities.</span></p>
CY2024	us-gaap	Year Founded YearFounded	1995
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, management’s judgments with respect to its revenue arrangements; liability related to the sale of future royalties; valuation of stock-based awards and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span></p>
CY2024	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	608000
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3360000
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3968000
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and of Significant Customers and Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term and long-term marketable securities and accounts receivable. The Company has all cash and investment balances at one accredited financial institution, including cash in amounts that exceed federally insured limits. The Company does not believe it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically generated the majority of its revenue from its collaborative research and license agreements. As of September 30, 2024 and 2023, accounts receivable consisted of amounts due from the Company’s principal collaborator (see Note 7).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is completely dependent on third-party manufacturers for product supply for preclinical and clinical research activities. The Company relies and expects to continue to rely exclusively on several manufacturers to supply the Company with its drug supply requirements related to these activities. These research programs would be adversely affected by a significant interruption in the supply from these third-party manufacturers.</span>
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	244401000
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1350000
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	369634000
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1423000
CY2024	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2023	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2022	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	210267000
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	686000
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	210953000
CY2023Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	285312000
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	802000
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	284522000
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	57735000
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35664000
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25047000
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23745000
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32688000
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11919000
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2336000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2371000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2973000
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6570000
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7037000
CY2024Q3	enta	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	3087000
CY2023Q3	enta	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	6120000
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1332000
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1632000
CY2024Q3	enta	Accrued Liabilities Manufacturing AccruedLiabilitiesManufacturing	930000
CY2023Q3	enta	Accrued Liabilities Manufacturing AccruedLiabilitiesManufacturing	3083000
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1628000
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	467000
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13547000
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18339000
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	3000000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0445
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0388
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0172
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y14D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y14D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.52
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.48
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.47
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.43
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	22.71
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	33.22
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4365000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	52.68
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1365000
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.99
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	16000
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.99
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	530000
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	42.05
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5184000
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.67
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1416000
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5184000
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	42.67
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1416000
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3482000
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	50.73
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	250000
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	93000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3295000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17650000
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	147000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2208000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21262000
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26795000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28216000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26969000
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26795000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28216000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26969000
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	31039000
CY2024	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2023	enta	Number Of Leases NumberOfLeases	3
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	10574000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	6230000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6294000
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	4720000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	5352000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	2375000
CY2024	us-gaap	Lease Cost LeaseCost	15294000
CY2023	us-gaap	Lease Cost LeaseCost	11582000
CY2022	us-gaap	Lease Cost LeaseCost	8669000
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	8283000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	6586000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4966000
CY2024	enta	Tenant Improvement Allowance Received TenantImprovementAllowanceReceived	9358000
CY2023	enta	Tenant Improvement Allowance Received TenantImprovementAllowanceReceived	1994000
CY2022	enta	Tenant Improvement Allowance Received TenantImprovementAllowanceReceived	0
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23960000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3817000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23910000
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y9M18D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8701000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8467000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8721000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8983000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9252000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	50595000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	94719000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	33003000
CY2024Q3	enta	Tenant Improvement Allowance TenantImprovementAllowance	-6249000
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	55467000
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1524000
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5275000
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53943000
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21238000
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	55467000
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	26513000
CY2024Q3	us-gaap	Security Deposit SecurityDeposit	92000
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-1936000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2522000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	193000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	299000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-449000
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	16000
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1743000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2821000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-433000
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.027
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.027
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.029
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.106
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.366
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.308
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.022
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.046
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.046
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.05
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.022
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.008
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.015
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.07
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0
CY2024	enta	Effective Income Tax Rate Reconciliation Interest On Net Operating Loss Carryback Claim EffectiveIncomeTaxRateReconciliationInterestOnNetOperatingLossCarrybackClaim	-0.012
CY2023	enta	Effective Income Tax Rate Reconciliation Interest On Net Operating Loss Carryback Claim EffectiveIncomeTaxRateReconciliationInterestOnNetOperatingLossCarrybackClaim	-0.008
CY2022	enta	Effective Income Tax Rate Reconciliation Interest On Net Operating Loss Carryback Claim EffectiveIncomeTaxRateReconciliationInterestOnNetOperatingLossCarrybackClaim	0
CY2024	enta	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate	0.106
CY2023	enta	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate	-0.001
CY2022	enta	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate	-0.001
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.015
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.022
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115120000
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67726000
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29298000
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-12124000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-47394000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-38428000
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	127244000
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115120000
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67726000
CY2024Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	49921000
CY2023Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	34855000
CY2024Q3	enta	Deferred Tax Assets Liabilty Related To The Sale Of Future Royalties DeferredTaxAssetsLiabiltyRelatedToTheSaleOfFutureRoyalties	36200000
CY2023Q3	enta	Deferred Tax Assets Liabilty Related To The Sale Of Future Royalties DeferredTaxAssetsLiabiltyRelatedToTheSaleOfFutureRoyalties	46560000
CY2024Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	18793000
CY2023Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	15549000
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14551000
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16974000
CY2024Q3	enta	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	13058000
CY2023Q3	enta	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	6485000
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7274000
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43000
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1387000
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1318000
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	50000
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	495000
CY2024Q3	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	0
CY2023Q3	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	189000
CY2024Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	161000
CY2023Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	214000
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	141395000
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	122682000
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	127244000
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115120000
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14151000
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7562000
CY2024Q3	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	8627000
CY2023Q3	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1525000
CY2024Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4362000
CY2023Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5456000
CY2024Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	999000
CY2023Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	581000
CY2024Q3	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	163000
CY2023Q3	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	0
CY2024Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14151000
CY2023Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7562000
CY2024Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2024	enta	Ownership Of Stockholders In Stock OwnershipOfStockholdersInStock	0.05
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies Other EffectiveIncomeTaxRateReconciliationTaxContingenciesOther	0.50
CY2024	us-gaap	Open Tax Year OpenTaxYear	2020
CY2019Q3	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	871
CY2024	us-gaap	Risks And Uncertainties In Entitys Business RisksAndUncertaintiesInEntitysBusiness	In response to the COVID-19 pandemic, the CARES Act was signed into law in March 2020. The CARES Act lifted certain deduction limitations originally imposed by the Tax Act. Under the CARES Act, the Company was permitted to carryback net operating losses for up to five years for losses generated in fiscal 2018 through fiscal 2021. Net operating loss carrybacks were previously prohibited under the Tax Act. The CARES Act also eliminated the 80% of taxable income limitations by allowing corporate entities to fully utilize net operating loss carryforwards to offset taxable income in fiscal years 2018, 2019 or 2020. In addition, the CARES Act made qualified improvement property eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act resulted in a $28,721 income tax benefit related to a federal net operating loss carryback at the previously enacted 35% rate in the Company’s consolidated financial statements during the year ended September 30, 2021.
CY2024Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	31999000
CY2023Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	31004000
CY2023Q3	us-gaap	Interest Receivable InterestReceivable	3292000
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	11000
CY2023Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	3000
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1056000
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	226000
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	882000
CY2024	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	11000
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	156000
CY2024	enta	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-140000
CY2023	enta	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	104000
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	905000
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1056000
CY2024	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1697000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1784000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1596000

Files In Submission

Name	View Source	Status
0000950170-24-131260-index-headers.html	Edgar Link	pending
0000950170-24-131260-index.html	Edgar Link	pending
0000950170-24-131260.txt	Edgar Link	pending
0000950170-24-131260-xbrl.zip	Edgar Link	pending
enta-20240930.htm	Edgar Link	pending
enta-20240930.xsd	Edgar Link	pending
enta-ex10_26.htm	Edgar Link	pending
enta-ex10_27.htm	Edgar Link	pending
enta-ex10_28.htm	Edgar Link	pending
enta-ex10_29.htm	Edgar Link	pending
enta-ex10_30.htm	Edgar Link	pending
enta-ex10_31.htm	Edgar Link	pending
enta-ex19_1.htm	Edgar Link	pending
enta-ex21_1.htm	Edgar Link	pending
enta-ex23_1.htm	Edgar Link	pending
enta-ex31_1.htm	Edgar Link	pending
enta-ex31_2.htm	Edgar Link	pending
enta-ex32_1.htm	Edgar Link	pending
enta-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img216965693_0.jpg	Edgar Link	pending
img216965693_1.jpg	Edgar Link	pending
img216965693_2.jpg	Edgar Link	pending
img216965693_3.jpg	Edgar Link	pending
img216965693_4.jpg	Edgar Link	pending
img216965693_5.jpg	Edgar Link	pending
img216965693_6.jpg	Edgar Link	pending
img216965693_7.jpg	Edgar Link	pending
img216965693_8.jpg	Edgar Link	pending
img52973840_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
enta-20240930_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

2024 Q4 Form 10-K Financial Statement

#000095017024131260 Filed on November 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA ENANTA PHARMACEUTICALS INC Stock $enta

2024 Q4 Form 10-K Financial Statement

#000095017024131260 Filed on November 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta